Comparative study of p53 immunoreactivity in benign and malignant prostate lesions
aDepartment of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, bDepartment of Pathology, Western Infirmary Glasgow, University of Glasgow, Glasgow, , cDepartment of Public Health and Health policy, University of Glasgow, Glasgow
Aim: Benign and malignant lesion of prostate have a high incidence in men. Over expression of p53 has been detected in some type of human malignancy. This study aimed to investigate the importance of p53 for differentiation of benign and malignant prostatic lesions. Methods: The accumulation of p53 was detected using immunohistochemical technique in the formalin-fixed and paraffin-embedded tissue specimens from 160 patients with primary prostate cancer and 50 patients with nodular hyperplasia. Results: There was no positive immunoreactivity for p53 in samples of nodular hyperplasia. 2.5% of low-grade cancers and 16.2% of high-grade cancer were immunoreactive for p53. There was a statistically significant difference between relative frequency of p53 immunoreactivity in low-grade and high-grade cancers. Conclusions: These results suggest that immunodetection of serum p53 could be recommended to determine a subgroup of less differentiated, more aggressive and hormone and radiation resistant prostatic cancers.
Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Nice, France; February 7 - 10, 2004; in poster session 893 (Molecular pathology).